Business Context and Reporting Period
This Form 8-K Current Report for IRIDEX Corporation covers events occurring on July 5, 2005. The filing primarily addresses significant executive leadership changes, including the appointment of a new Chief Executive Officer (CEO) and the resignation of the previous CEO and Chairman of the Board.
Key Financial Metrics and Agreements
The filing details specific compensation terms for the new CEO, Barry G. Caldwell, rather than reporting company-wide financial performance metrics such as revenue or cash flow.
- Base Salary: $300,000 annualized.
- Stock Options: Two grants totaling 300,000 shares (65,896 ISO shares and 234,104 Stand-Alone shares) at an exercise price of $6.07 per share.
- Vesting Schedule: 25% vests on the first anniversary (July 5, 2006), with the remainder vesting monthly over the subsequent 36 months.
- Severance (Change of Control): 12 to 18 months of base salary plus 50% acceleration of unvested equity, depending on the timing of termination relative to the agreement date.
- Severance (Non-Change of Control): 6 to 12 months of base salary, depending on the timing of termination.
Material Changes Versus Prior Period
The filing reports the following material changes in corporate governance and personnel effective July 5, 2005:
- CEO Transition: Theodore A. Boutacoff resigned as CEO and transitioned to the role of Senior Principal Advisor. Barry G. Caldwell was appointed as the new CEO.
- Board Changes: Donald Hammond resigned as Chairman of the Board but remains a director. Theodore A. Boutacoff was appointed as the new Chairman of the Board. Barry G. Caldwell was appointed as a new member of the Board of Directors.
Outlook, Risks, and Contingencies
The filing outlines specific contingencies regarding executive compensation and employment stability:
- Relocation Repayment: If Mr. Caldwell voluntarily terminates employment within 12 months, he must repay relocation benefits on a pro-rata basis.
- Separation Agreement Requirement: Severance payments and continued benefits are contingent upon Mr. Caldwell executing a separation agreement and release of claims.
- Clawback Provisions: All severance payments and company-paid benefits cease immediately if Mr. Caldwell breaches the separation agreement during the payment period.
- Termination for Cause: In the event of termination for Cause or voluntary resignation without Good Reason, Mr. Caldwell receives only earned salary and accrued benefits, with no severance or accelerated equity vesting.
Key Facts for Investor Verification
- Verify the total dilution impact of the 300,000 new stock options granted to the CEO.
- Confirm the specific definitions of "Cause" and "Good Reason" in the attached agreements to understand the triggers for severance.
- Assess the strategic rationale for appointing a CEO with a background in ophthalmic pharmaceuticals and surgical equipment (Alcon Laboratories) to a medical laser company.
- Note that this filing does not contain updated revenue, profit, or liquidity data for the company.